AU660090B2 - Contact lens care product for hard and soft contact lenses - Google Patents
Contact lens care product for hard and soft contact lenses Download PDFInfo
- Publication number
- AU660090B2 AU660090B2 AU41252/93A AU4125293A AU660090B2 AU 660090 B2 AU660090 B2 AU 660090B2 AU 41252/93 A AU41252/93 A AU 41252/93A AU 4125293 A AU4125293 A AU 4125293A AU 660090 B2 AU660090 B2 AU 660090B2
- Authority
- AU
- Australia
- Prior art keywords
- contact lens
- care product
- salt
- lens care
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 30
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 26
- 229940123208 Biguanide Drugs 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 23
- -1 aminopropyl biguanide Chemical compound 0.000 claims description 21
- 239000000872 buffer Substances 0.000 claims description 18
- 229960000281 trometamol Drugs 0.000 claims description 14
- 238000004140 cleaning Methods 0.000 claims description 10
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 8
- 230000000249 desinfective effect Effects 0.000 claims description 8
- 229920001992 poloxamer 407 Polymers 0.000 claims description 7
- 229940044476 poloxamer 407 Drugs 0.000 claims description 7
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 4
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- 229920001090 Polyaminopropyl biguanide Polymers 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 229940093424 polyaminopropyl biguanide Drugs 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 34
- 238000009472 formulation Methods 0.000 description 13
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 230000009036 growth inhibition Effects 0.000 description 6
- 241000228245 Aspergillus niger Species 0.000 description 5
- 241000222122 Candida albicans Species 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 229940095731 candida albicans Drugs 0.000 description 5
- 239000002054 inoculum Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 229940035437 1,3-propanediol Drugs 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 108091006629 SLC13A2 Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 150000002688 maleic acid derivatives Chemical class 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Chemical compound CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 1
- MLONYBFKXHEPCD-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO.OCC(N)(CO)CO MLONYBFKXHEPCD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 231100000050 cytotoxic potential Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229940073585 tromethamine hydrochloride Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Eyeglasses (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Detergent Compositions (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Description
Our Ref: 471956 P/00/011 Regulation 3:2
AUSTRALIA
Patents Act 1990
ORIGINAL
COMPLETE SPECIFICATION STANDARD PATENT 660090 ApplicLnt(s): Address for Service: Ciba-Geigy AG Klybeckstrasse 141 CH-A002 BASLE
SWITZERLAND
DAVIES COLLISON CAVE Patent Trade Mark Attorneys Level 10, 10 Barrack Street SYDNEY NSW 2000 Contact lens care product for hard and soft contact lenses
U
I
Invention Title: The following statement is a full description of this invention, including the best method of performing it known to me:- 5020 -1- Contact lens care product for hard and soft contact lenses The present invention relates to a contact lens care product for hard and soft contact lenses, comprising a (poly)aminopropyl biguanide and a special buffer.
Contact lens care product comprising an aminopropyl biguanide are already known. For example, GB 1 432 345 describes ophthalmic compositions and compositions for disinfecting contact lenses comprising an ophthalmologically acceptable polymeric biguanide. Only phosphate buffers are disclosed as suitable buffers in that context.
EP-AI-180 309 also discloses disinfecting and preserving solutions for contact lenses, comprising a biguanide and a buffer. The biguanide is again of the aminopropyl biguanide type. As buffer especially borate buffers are proposed. Additional buffers mentioned are citrate buffers, bicarbonate buffers and mixed phosphate buffers.
In contrast, the present invention relates to a contact lens care product comprising an aminopropyl biguanide or a salt thereof and as buffer trometamol or a homolog thereof having up to 10 carbon atoms or a salt thereof, wherein the aminopropyl biguanide is a compound of formula I NH NH
H
2
N-(CH
2 )3CH 2 3 -NH-C-NH- -NH-(CH2) C H2 2 I) wherein n is an integer from I to 500, or a salt of a compound of formula I, or wherein the aminopropyl biguanide is a mixture of a compound of formula I, or a salt thereof, with a compound of formula II, or a salt thereof, NH NH
NH
30 H2N-(CH2)3 H2)3-NH-C-NH-(-NH-(CH2)(CH2)3-NH-I-NH-CN (1) la wherein n is likewise an integer form 1 to 500.
The invention relates also to the use of such a contact lens care product for cleaning and disinfecting contact lenses.
The aminopropyl biguanides to be used according to the invention are especially those of formula I NH NH
H
2
N-(CH
2 )3 H2)3-NH-C-NH- -NH-(CH 2 2)3-NH 2
(I)
wherein n is an integer from 1 to 500; it is also possible to use salts of compounds of formula I, especially ophthalmologically acceptable salts thereof.
The compounds of formula I are known. Their preparation is described, for example, in 0 i t -2- GB 702 268 and GB 1 152 243. In addition, those compounds are also commercially available, for example as Vantocil®, Cosmocil® or as Arlagard®E from ICI Chemicals.
Depending on the manner in which they have been prepared, the compounds of formula I may comprise certain amounts of a secondary product of formula II NH NH
NH
11
II
H2N-(CH2)3 CH )3-NH-C-NH- -NH-(CH2) (CH2)3-NH-C-NH-CN or salts thereof, wherein n is likewise an integer from 1 to 500. Mixtures of'compounds of formula I with those of formula II can likewise be used according to the invention. The proportion of compounds of formula I, based on the total amount of compounds of formula I and compounds of formula II, is preferably less than 20 percent by weight, more preferably less than from 2 to 10 percent by weight and is especially preferably zero percent by weight.
The index n in formulae I and II is preferably from 1 to 200, especially from 2 to 100, more especially from 2 to 50 and most especially from 3 to 12. Depending on the value of the index n in formula I or I, the molecular weight of the aminopropyl biguanides that can be used is as low as the molecular weight of the monomer of formula I (n or in the range of approximately 600 to 1600 if oligomers are used, i.e. when n is, for example, from 3 to 8, or alternatively in the range of from approximately 50 000 to approximately 000 if n is significantly higher, for example approximately 270 to 500.
In the contact lens care products according to the invention, the compound of formula I is used preferably in an amount, based on the total amount of the contact lens care product, which is advantageously formulated as an aqueous solution, of from 0.1 to 100 ppm (0.00001 0.01 percent by weight), especially in an amount of from 0.5 to 50 ppm (0.00005 0.005 percent by weight) and more especially in an amount of from 1 to 10 ppm (0.0001 0.001 percent by weight), for example 1, 2 or 5 ppm.
Salts of compounds of formula I and formula II that are suitable within the scope of the present invention are water-soluble salts that are advantageously ophthalmologically acceptable. Suitable salts are those with inorganic or organic acids, for example hydrochlorides, hydrobromides, borates, acetates, gluconates, sulfonates, maleates, ascorbates, tartrates or citrates.
The trometamol and its homologs having up to 10, preferably from 5 to 7, carbon atoms used according to the invention preferably are the compounds of formula III
(CH
2 )y-OH HO-(CH2)x-C-NH2
(CH
2
),-OH
wherein x, y and z are each independently of the others an integer, at least 1, and the sum of x, y and z is from 3 to 9, preferably from 3 to 6, or a salt thereof. Special preference is given to 2-amino-2-hydroxymethyl- 1,3-propanediol (trometamol), which corresponds to a compound of formula III wherein each of x and y and z is 1. The compound trometamol is also referred to as tris buffer.
Trometamol and its homologs having up to 10 carbon atoms are already known. Their use in medicaments for the treatment of inflammations of the eye has already been disclosed in EP-A2-242 328. Compositions for the disinfection of contact lenses, comprising 1.2 tromethamine/tromethamine hydrochloride and 1 ppm polyhexamethylene biguanide hydrochloride, are already known from WO 92/11876. Compounds of formula II are, moreover, also commercially available.
The amount of trometamol used as buffer in the contact lens care products according to the invention, based on the total amount of the contact lens care product, is preferably from 0.05 to 5 percent by weight, preferably from 0.1 to 2.5 percent by weight and especially preferably from approximately 0.2 to approximately 1.5 percent by weight. The amount of trometamol used as buffer in the contact lens care products according to the invention, based on the total amount of the contact lens care product, is more especially '7 from 0.05 to less than 1.2 percent by weight or from 0.05 to less than 0.8 percent by weight, very especially from 0.1 to 0.6 percent by weight, especially from 0.1 to less than S, 0.6 percent by weight, for example up to 0.5 percent by weight.
2-Amino-2-hydroxymethyl-1,3-propanediol or a homolog thereof having up to 10 carbon atoms, or a salt thereof, can be used alone as buffer. Alternatively, one of the abovementioned compounds can be used together with a sal thereof. Again, preference is given -4here to the use of ophthalmologically acceptable salts, such as the salts mentioned above in connection with compounds of formula I. Especially suitable are the hydrochlorides or maleates of compounds of formula III, for example, a combination of 2-amino- 2-hydroxymethyl-1,3-propanediol with the hydrochloride of 2-amino-2-hydroxymethyi- 1,3-propanediol, or a combination of 2-amino-2-hydroxymethyl-1,3-propanediol with the maleate of 2-amino-2-hydroxymethyl-1,3-propanediol or 2-amino-2-hiydroxymethyl- 1,3-propanediol, to which small amounts of hydrochloric acid are added.
The contact lens care products according to the invention preferably do not comprise buffers other than compounds of formula Il. They may, however, comprise other buffers in addition to one or more compounds of formula III.
The contact lens care products according to the invention are preferably formulated in such a manner that they are 'sotonic with lachrymal fluid. They may in general comprise additives that are customary for contact lens care products. Those include, for example, compounds that influence tonicity, surface-active compounds, compounds tfhat influence viscosity, or complex formers. The contact lens care products according to the invention comprise those or other customary additives in amounts that vary within the range of the values familiar to the person skilled in the art.
A solution that is isotonic with lachrymal fluid is generally understood, to be a solution the concentration of which corresponds to the concentration of a 0.9 sodium chloride solution, Departures therefrom are entirely possible, provided that the contact lenses to be treated a'e not damaged thereby. Isotonicity with lachrymal fluid or a different desired S tonicity can be established by the addition of organic or inorganic compounds that influence tonicity. The former can be used, for example, in amounts of approximately 1 to percent by weight, the latter in amounts of approximately 0.1 to 1.3 percent by weight.
In general, the amount of the compound that influences tonicity that is added is such that Sthe tonicity of the composition according to the invention is especially in the range of from 200 to 450 milliosmols, preferably in the range of from approximately 270 to approximately 330 milliosmols. Typical organic compounds of that type are, for example, glycerol, urea, propylene glycol or sugars, such as mannitol or sorbitol, and typical inorganic compounds of that type are especially potassium chloride and sodium chloride.
Mixtures of those compounds with one another can also be used according to the invention.
Suitable surface-active compounds are mentioned, for example, in EP-A2-180 309.
Examples of especially suitable representatives that can be used according to the invention are poloxamer types and miranol types. Other representatives are known to a person skilled in the art. Those compounds can be used, for example, in amounts of up to percent by weight, especially in amounts of from 0.4 to 5 percent by weight.
Suitable compounds that influence viscosity are also known to a person skilled in the art.
Examples of especially suitable representatives that can be used according to the invention are polyvinyl alcohol, hydroxyethylcellulose, hydroxypropylmethylcellulose and polyacrylic acid. Typical amounts for those compounds are from 0.1 to 2 percent by weight.
An especially suitable complex former is especially ethylenediaminetetraacetic acid, abbreviated to EDTA, and salts thereof, such as sodium salts. Typical amounts for those compounds are from 0.01 to 1 percent by weight.
The contact lens care products according to the invention are suitable for all types of contact lenses. These include especially so-called hard and soft contact lenses, also I so-called hard-flexible or highly gas-permeable contact lenses. The contact lens care products according to the invention exhibit an antimicrobial action and, also, a cleaning I action. Depending on the specific intended use, the contact lens care products according to the invention can be used as cleaning solutions, disinfectants, or, for example, as solutions for storing, rinsing, wetting or soaking contact lenses. All those solutions are distinguished by good cleaning and disinfecting action and a high degree of tolerability in a single solution.
In addition, while exhibiting better antimicrobial activity, the contact lens care products according to the invention surprisingly exhibit significantly better cytotoxicity properties than do the care products known from the prior art, for example Bausch Lomb's Kombi solution. The overall spectrum of properties of the contact lens care products according to the invention is therefore considered to be significantly superior to the properties of the contact lens care products known from the prior art.
The contact lens care products according to the invention are prepared in a manner known per se, especially by conventional mixing of the constituents with water or dissolving of the constituents i water.
-6- The compositions according to the invention are especially suitable for cleaning and disinfecting contact lenses. The contact lens care products according to the invention are used in a manner known per se, for example by bringing a contact lens into contact with the contact lens care product for a period of time sufficient for cleaning or disinfection.
Depending on the type of lens and the degree of contamination, a period of from several minutes to about 24 hours, preferably up to approximately 4 to 12 hours, is sufficient.
A preferred solution according to the invention comprises, for example, aminopropyl biguanide 2-amino-2-hydroxymethyl-1,3-propanediol 2-amino-2-hydroxymethyl-1,3-propanediol HC1 0.0005 to 0.05 mg/ml 0.67 to 4.03 mg/ml 2.64 to 4.02 mg/ml, q II
III
il i I I ~I I the total amount of buffer being preferably less than 8 mg/ml and especially less than 6 mg/ml, and may preferably also comprise: NaC1 or KCl 3 to 9 mg/ml especially 5.5 to 9 mg/ml 5 to 30 mg/ml 0.1 to 2 mg/ml.
surface-active compound
EDTA
A solution according to the invention that is likewise preferred comprises, for example,
I.
1114I 1*011 aminopropyl biguanide 2-amino-2-hydroxymethyl-1,3-propanediol 0.0005 to 0.05 mg/ml 1.00 to 4.00 mg/ml especially about 2.5 mg/ml and small amounts of HC1 to establish the desired pH range.
The desired pH range of the compositions according to the invention is especially approximately 7.0 to 7.5, preferably from 7.1 to 7.4 and especially preferably 7.3.
The following Examples serve to illustrate the invention. They are not, however, intended to limit the scope of the invention in any way, and especially not to the subject-matter of the Examples.
-7- Example 1: Formulation for soft contact lenses 1 ml of solution comprises: aminopropyl biguanide (Arlagard®) 0.005 Mg 2-amnino-2-hydroxymethyl- 1,3-propanediol 0.97 Mg 2-amino-2-hydroxymethy1-1 ,3-propanediol HCl 6.61 mg NaCI 6.6 Mg poloxamer 407 10 Mg EDTA 1 Mg.
Example 2: Formulation for hard contact lenses 1 ml of solution comprises: aminopropyl biguanide (Arlagard®) 0.005 Mg twt 2-amino-2-hydroxymethyl-1,3-propanedioI 0.97 mg NaCI 6.6 mg poloxamer 407 polyvinyl alcohol 14 mg.
a iExample 3: Formulation for soft contact lenses 1lml of solution comprises: aminopropyl biguanide (Arlagard E®R) 0.005 Mg 2-amino-2-hydroxymethyl- 1,3-propanecliol 1.39 mg 2-amino-2-hydroxymethyl-1,3-propanediol HI 6.06 mg NaCi 5.5 Mg poloxamer 407 10 Mg EDTA 1 Mg.
Example 4: Antimicrobial activity The formulation of Example 3 is tested against the following test organisms: Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans, Aspergillus niger. The following Table shows the initial inoculum as well as the number of organisms still to be found after the formulation of Example 3 has been allowed to act for a period of 4 hours and of 6 hours: Test organism initial number of number of inoculum organisms organisms after after 4 hours 6 hours Escherichia coli 6.8 10 5 0 0 Staphylococcus aureus 8.9 105 0 0 Pseudomonas aeruginosa 1.0 106 0 0 Candida albicans 1.1 10 6 2.7 -105 1.8 105 Aspergillus niger 1.1 106 6.2 10 5 1.1 106 In contrast, the following values are determined for Bausch Lomb's Renu solution comprising aminopropyl biguanide (0.5 ppm) and a borate buffer: Test organism initial number of number of inoculum organisms organisms after after 4 hours 6 hours Escherichia coli 6.8 105 9.5 101 4.3 101 Staphylococcus aureus 8.9 105 5.7 101 3.8 101 Pseudomonas aeruginosa 1.0 106 0 0 S Candida albicans 1.1. 10 6 4.9 105 6.2 105 Aspergillus niger 1.1 106 5.5 10 5 4.3 105 Example 5: Cytotoxicity test In order to determine the cytotoxic potential, the formulation of Example 3 is subjected to the growth inhibition test and compared with Bausch Lomb's Kombi solution. In this test the decrease in cell growth in the presence of toxic compounds is determined by comparing the protein content of treated cell cultures with the protein content of untreated cell cultures after 72 hours' incubation. The test solutions are serially diluted with the cell culture medium (DMEM-FCS). L 929 cell cultures are incubated for 72 hours in the presence of solutions of various concentrations. It is found that the solution according to presence of solutions of various concentrations. It is found that the solution according to the invention induces cytotoxic effects only at concentrations of 20 v/v, while the Kombi solution already induces cytotoxic effects at concentrations of 5 v/v.
In the test carried out, the protein content is a measure of the cell growth or the inhibition of growth induced by toxic substances. Growth inhibition of more than 30 compared with untreated cultures is considered to be a clear cytotoxic effect.
Solution Formulation according to Example 3 Concentration of the solution v/v] 20.0 10.0 5.0 2.5 1.3 0.6 Growth inhibition 32 11 4 4 2 0 Solution Kombi solution from Bausch Lomb Concentration of the solution v/v] 20.0 10.0 5.0 2.5 1.3 0.6 Growth inhibition 92 68 40 25 11 7 These results demonstrate that the Kombi solution already induces cytotoxic effects at a dilution lower by a factor of 4, namely at 5 v/v, compared with the formulation according to Example 3 with which such effects occur only with 20 v/v solutions.
Example 6: Formulation for hard contact lenses 1 ml of solution comprises: polyaminopropyl biguanide (CosmocilO) 0.002 mg 2-amino-2-hydroxymethyl-1,3-propanediol 2.5 mg NaCl 7.5 mg poloxamer 407 10 mg hydroxyethylcellulose 3.2 mg EDTA 1 mg HCI to adjust pH Example 7: Formulation for soft contact lenses 1 ml of solution comprises: polyaminopropyl biguanide (Cosmocil®) 0.001 mg 2-amino-2-hydroxymethyl-1,3-propanediol 2.45 mg NaC1 7.4 mg poloxamer 407 1.0 mg EDTA 0.25 mg HC1 to adjust pH Example 8: Antimicrobial activity The formulation according to Example 6 is tested against the following test organisms: Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans, Aspergillus niger. The following Table indicates the initial inoculum and the number of organisms still to be found after the formulation of Example 6 has been allowed to act for a period of 6 hours: Test organism initial number of inoculum organisms after 6 hours Escherichia coli 1.1 10 6 0 Staphylococcus aureus 1.4 106 0 Pseudomonas aeruginosa 1.3 10 6 0 Candida albicans 1.2 106 4.1 105 Aspergillus niger 5.7 105 2.8 105 Example 9: Cvtotoxicity test Analogously to Example 5 the formulation according to Example 6 is subjected to the growth inhibition test. The test shows that the solution according to the invention induces only extremely slight cytotoxic effects even at concentrations of 20 v/v, while the Kombi solution already induces significant cytotoxic effects at concentrations of 5 v/v (see Example 11 Solution according to Example 6 Concentration of solution v/v] 20.0 10.0 5.0 2.5 1.3 0.6 growth inhibition 12 5 0 0 0 3
Claims (5)
1. A contact lens care product comprising an aminopropyl biguanide or a salt thereof and as buffer trometamol or a homolog thereof having up to 10 carbon atoms or a salt thereof, wherein the aminopropyl biguanide is a compound of formula I NH NH H2N-(CH2)3 H2)3-NH-C-NH--H-(C2) CH2)3-NH2 wherein n is an integer from 1 to 500, or a salt of a compound of formula I, or wherein the aminopropyl biguanide is a mixture of a compound of formula I, or a salt thereof, with a compound of formula II, or a salt thereof, NH NH NH H2N-(CH2)3 CH2)3-NH-C-NH--NH-(CH2) -(CH)3-NH--N H-CN wherein n is likewise an integer from 1 to 500.
2. A contact lens care product according to claim 1 wherein the buffer is a compound of formula I (CH 2 )y-OH HO-(CH2)x-C-NH2 (I) S(CH 2 wherein x, y and z are each independently of the others an integer, at least 1, and the sum of x, y and z is from 3 to 9, or a salt thereof.
3. A contact lens care product according to claim 1 wherein the aminopropyl biguanide is a compound of formula I N H N H H2N-(CH2)3CH2)3- C--C-NH- -NH-(CH2
13- wherein n is an integer from 1 to 500, or a salt of a compound of formula I, and wherein the buffer is trometamol or a salt thereof. 4. A contact lens care product according to claim 1 comprising from 0.05 to less than 1.2 percent by weight trometamol or a homolog thereof having up to 10 carbon atoms or a salt thereof. A contact lens care product according to claim 1 comprising from 0.05 to less than 0.8 percent by weight trometamol or a homolog thereof having up to 10 carbon atoms or a salt thereof. 6. A contact lens care product according to claim 1 comprising from 0.1 to 0.6 percent by weight trometamol or a homolog thereof having up to 10 carbon atoms or a salt thereof. 7. A contact lens care product according to claim 1 comprising aminopropyl biguanide 2-amino-2-hydroxymethyl-1,3-propanedioI 0.0005 to 0.05 mg/ml 1.00 to 4.00 mg/ml especially about 2.5 mg/ml and HC1 to establish a pH of from 7.0 to 8. A contact lens care product according to claim 1 comprising in addition one or more additives selected from compounds that influence tonicity, surface-active compounds, compounds that influence viscosity and complex formers. S 9. A contact lens care product according to claim 1 comprising polyaminopropyl biguanide (Cosmocil®) a* 2-amino-2-hydroxymethyl-1,3-propanediol NaCI poloxamer 407 hydroxyethylcellulose S EDTA and HCI to adjust the pH. 10. A contact lens care product according to claim 1 comprising aminopropyl biguanide (Cosmocil®) @S 0.002 mg/ml 2.5 mg/ml 7.5 mg/ml 10 mg/ml 3.2 mg/ml 1 mg/ml 0.001 mg/ml
14- 2-amino-2- hydroxymetixyl- 1,3-propanediol NaCI poloxamer 407 EDTA and HC1 to adjust the pH. 2 mg/ml 7.4 mg/m 1.0 mg/ml 0.25 mg/ml 11. A method of cleaning and/or disinfecting a contact lens which comprises bringing a contact lens care product according to claim 1 into contact with a contact lens for a period of time sufficient for cleaning or disinfection. 12. A contact lens care product substantially as herein described with reference to any one of the Examples, (excluding prior art comparison examples). 13. A method of cleaning and/or disinfecting a contact lens substantially as herein described with reference to any one of Examples 4, 5, 8 or 9 (excluding the prior art comparison examples). DATED this 31st day of March, 1995. I. CIBA-GEIGY AG By Its Patent Attorneys DAVIES COLLISON CAVE 44? CLIV-19128/A/CVE 34 Contact lens care product for hard and soft contact lenses Abstract The present invention relates to contact lens car; products comprising an aminopropyl biguanide or a salt thereof, especially a compound of formula I NH NH H 2 N-(CH 2 3 CH 2 3 -NH-(CH 2 ).(CH 2 3 -NH 2 (I) wherein n is an integer from 1 to 500, or a salt thereof, and the so-called tris buffer (trometamol) or a homolog thereof having up to 10 carbon atoms or a salt thereof. The invention relates also to the use of such a contact lens care product for cleaning and disin- fecting contact lenses. lot 4 1 t
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP92810467 | 1992-06-17 | ||
| EP92810467 | 1992-06-17 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU4125293A AU4125293A (en) | 1993-12-23 |
| AU660090B2 true AU660090B2 (en) | 1995-06-08 |
| AU660090C AU660090C (en) | 1997-08-14 |
Family
ID=
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4836986A (en) * | 1984-09-28 | 1989-06-06 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
| AU5992594A (en) * | 1993-01-07 | 1994-08-15 | Polymer Technology Corporation | Preservative system for contact lens solutions |
| AU653768B2 (en) * | 1990-12-27 | 1994-10-13 | Advanced Medical Optics, Inc. | Method and composition for disinfecting contact lenses |
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4836986A (en) * | 1984-09-28 | 1989-06-06 | Bausch & Lomb Incorporated | Disinfecting and preserving systems and methods of use |
| AU653768B2 (en) * | 1990-12-27 | 1994-10-13 | Advanced Medical Optics, Inc. | Method and composition for disinfecting contact lenses |
| AU5992594A (en) * | 1993-01-07 | 1994-08-15 | Polymer Technology Corporation | Preservative system for contact lens solutions |
Also Published As
| Publication number | Publication date |
|---|---|
| FI932683A0 (en) | 1993-06-11 |
| NO932224L (en) | 1993-12-20 |
| CA2098472A1 (en) | 1993-12-18 |
| SG47420A1 (en) | 1998-04-17 |
| FI932683A7 (en) | 1993-12-18 |
| IL105972A (en) | 1999-09-22 |
| JP3423357B2 (en) | 2003-07-07 |
| CA2098472C (en) | 2004-01-06 |
| ZA934268B (en) | 1993-12-17 |
| FI932683L (en) | 1993-12-18 |
| JPH0667123A (en) | 1994-03-11 |
| NO307450B1 (en) | 2000-04-10 |
| MX9303587A (en) | 1994-01-31 |
| ATE337023T1 (en) | 2006-09-15 |
| TW203128B (en) | 1993-04-01 |
| AU4125293A (en) | 1993-12-23 |
| NO932224D0 (en) | 1993-06-16 |
| IL105972A0 (en) | 1993-10-20 |
| NZ247890A (en) | 1994-12-22 |
| DE59310389D1 (en) | 2006-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2875887B2 (en) | Contact lens disinfection method and composition | |
| CN1157227C (en) | Use of low molecular weight amino alcohols in ophthalmic compositions | |
| US9272066B2 (en) | Ophthalmic and contact lens solutions using choline | |
| US6995123B2 (en) | Use of multifunctional surface active agents to clean contact lenses | |
| CN1477929A (en) | Aqueous Disinfection System | |
| US7364723B1 (en) | Liquid preparation for contact lenses | |
| CA2098472C (en) | Contact lens care product for hard and soft contact lenses | |
| EP1732617B1 (en) | Alkylamine as an antimicrobial agent in ophthalmic compositions | |
| US6316669B1 (en) | Bis-amido polybiguanides and the use thereof to disinfect contact lenses and preserve pharmaceutical compositions | |
| EP2262521B1 (en) | Ophthalmic compositions comprising a dipeptide with a glycine moiety | |
| US6423748B1 (en) | Amido polybiguanides and the use thereof as antimicrobial agents | |
| JP2007513951A (en) | Use of organic buffers to enhance the antimicrobial activity of pharmaceutical compositions | |
| AU2014242073B2 (en) | Synergistic ophthalmic compositions for disinfecting contact lenses | |
| EP1792972A1 (en) | Use of multifuctional surface active agents to clean contact lenses | |
| HK1075464B (en) | Use of multifunctional surface active agents to clean contact lenses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |